SCM
ACET icon

Stonepine Capital Management’s Adicet Bio ACET Stock Holding History

Stonepine Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.12M Buy
245,518
+23,563
+11% +$186K 1.2% 26
2026
Q1 		$1.51M Buy
221,955
+1,944
+0.9% +$14.6K 0.61% 28
2025
Q4 		$1.85M Buy
+220,011
New +$2.43M 1.35% 24
2025
Q2 		– Sell
-31,767
Closed -$204K – 60
2025
Q1 		$204K Sell
31,767
-11,983
-27% -$171K 0.2% 47
2024
Q4 		$673K Buy
43,750
+5,660
+15% +$107K 0.54% 36
2024
Q3 		$878K Hold
38,090
– – 0.55% 27
2024
Q2 		$737K Buy
38,090
+29,243
+331% +$784K 0.67% 17
2024
Q1 		$333K Buy
+8,847
New +$366K 0.26% 17
2020
Q1 		– Sell
-730
Closed -$122K – 28
2019
Q4 		$122K Buy
+730
New +$370K 0.09% 22

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Stonepine Capital Management's ACET Position: Q2 2026 in Review

Stonepine Capital Management increased its Adicet Bio (ACET) stake by 11% in Q2 2026, buying an estimated $186K and bringing the position to 245,518 shares worth $2.12M. The position accounts for 1.2% of the portfolio, ranked #26.

Stonepine Capital Management first reported a position in ACET in Q4 2019 and has held it in 9 quarters since. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

  • Stonepine Capital Management held 245,518 shares of Adicet Bio worth $2.12M as of Q2 2026.
  • Stonepine Capital Management bought 23,563 Adicet Bio shares in Q2 2026, an estimated $186K.
  • Adicet Bio made up 1.2% of Stonepine Capital Management's portfolio in Q2 2026, its #26 holding.
  • Stonepine Capital Management first reported a position in Adicet Bio in Q4 2019 and has held it in 9 quarters since.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.